Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.

Antibodies, Monoclonal / therapeutic use Antibodies, Monoclonal, Humanized Antibodies, Neutralizing / therapeutic use Antibodies, Viral Humans Membrane Glycoproteins / genetics Neutralization Tests SARS-CoV-2 Spike Glycoprotein, Coronavirus Viral Envelope Proteins COVID-19 Drug Treatment

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
06 2022

Historique:

received: 06 03 2022

accepted: 22 03 2022

pubmed: 25 3 2022

medline: 22 6 2022

entrez: 24 3 2022

Statut: ppublish

Résumé

The severe acute respiratory syndrome coronavirus 2 Omicron BA.1 sublineage has been supplanted in many countries by the BA.2 sublineage. BA.2 differs from BA.1 by about 21 mutations in its spike. In this study, we first compared the sensitivity of BA.1 and BA.2 to neutralization by nine therapeutic monoclonal antibodies (mAbs). In contrast to BA.1, BA.2 was sensitive to cilgavimab, partly inhibited by imdevimab and resistant to adintrevimab and sotrovimab. We then analyzed sera from 29 immunocompromised individuals up to 1 month after administration of Ronapreve (casirivimab and imdevimab) and/or Evusheld (cilgavimab and tixagevimab) antibody cocktails. All treated individuals displayed elevated antibody levels in their sera, which efficiently neutralized the Delta variant. Sera from Ronapreve recipients did not neutralize BA.1 and weakly inhibited BA.2. Neutralization of BA.1 and BA.2 was detected in 19 and 29 out of 29 Evusheld recipients, respectively. As compared to the Delta variant, neutralizing titers were more markedly decreased against BA.1 (344-fold) than BA.2 (nine-fold). We further report four breakthrough Omicron infections among the 29 individuals, indicating that antibody treatment did not fully prevent infection. Collectively, BA.1 and BA.2 exhibit noticeable differences in their sensitivity to therapeutic mAbs. Anti-Omicron neutralizing activity of Ronapreve and, to a lesser extent, that of Evusheld is reduced in patients' sera.

Identifiants

DOI: 10.1038/s41591-022-01792-5 PMID: 35322239

pubmed: 35322239

doi: 10.1038/s41591-022-01792-5

pii: 10.1038/s41591-022-01792-5

doi:

Substances chimiques

Antibodies, Monoclonal 0

Antibodies, Monoclonal, Humanized 0

Antibodies, Neutralizing 0

Antibodies, Viral 0

Membrane Glycoproteins 0

Spike Glycoprotein, Coronavirus 0

Viral Envelope Proteins 0

spike protein, SARS-CoV-2 0

tixagevimab 0

cilgavimab 1KUR4BN70F

sotrovimab 1MTK0BPN8V

imdevimab 2Z3DQD2JHM

casirivimab J0FI6WE1QN

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

1297-1302

Commentaires et corrections

Type : CommentIn

Informations de copyright

Références

Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686 (2022).

doi: 10.1038/s41586-022-04411-y

Carreño, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022).

doi: 10.1038/s41586-022-04399-5

Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022).

doi: 10.1038/s41586-021-04386-2

Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2021).

doi: 10.1038/s41586-021-04389-z

Garcia-Beltran, W. F. et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457–466 (2022).

doi: 10.1016/j.cell.2021.12.033

Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663 (2022).

doi: 10.1038/s41586-021-04385-3

Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022).

doi: 10.1038/s41586-021-04387-1

Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449 (2020).

doi: 10.1038/s41586-020-2548-6

Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).

doi: 10.1038/s41586-021-04388-0

VanBlargan, L. A. et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med 28, 490–495 (2022).

doi: 10.1038/s41591-021-01678-y

Yamasoba, D. et al. Virological characteristics of SARS-CoV-2 BA.2 variant. Preprint at https://www.biorxiv.org/content/10.1101/2022.02.14.480335v1 (2022).

Zhou, H., Tada, T., Dcosta, B. M. & Landau, N. R. Neutralization of SARS-CoV-2 omicron BA.2 by therapeutic monoclonal antibodies. Preprint at https://www.biorxiv.org/content/10.1101/2022.02.15.480166v2 (2022).

Yu, J. et al. Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants. NEJM https://doi.org/10.1056/NEJMc2201849 (2022).

Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature https://doi.org/10.1038/s41586-022-04594-4 (2022).

Cathcart, A. L. et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. Preprint at https://www.biorxiv.org/content/10.1101/2021.03.09.434607v10 (2021).

Mykytyn, A. Z. et al. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants. Preprint at https://www.biorxiv.org/content/10.1101/2022.02.23.481644v1.full (2022).

Crowe, Jr., J. E. C. Human antibodies for viral infections. Annu. Rev. Immunol. https://doi.org/10.1146/annurev-immunol-042718-041309 (2022).

Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382–393 (2021).

doi: 10.1038/s41577-021-00542-x

O’Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. N. Engl. J. Med. 385, 1184–1195 (2021).

doi: 10.1056/NEJMoa2109682

Loo, Y.-M. et al. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans. Sci. Transl. Med. 14, eabl8124 (2022).

doi: 10.1126/scitranslmed.abl8124

AstraZeneca. New analyses of two AZD7442 COVID-19 phase III trials in high-risk populations confirm robust efficacy and long-term prevention. https://www.astrazeneca.com/media-centre/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention.html (2021).

National Institutes of Health. All Variants. Reported in vitro Therapeutic Activity. https://opendata.ncats.nih.gov/variant/activity (2022).

Agarwal, A. et al. A living WHO guideline on drugs for covid-19. BMJ 370, m3379 (2020).

doi: 10.1136/bmj.m3379

Buchrieser, J. et al. Syncytia formation by SARS‐CoV‐2 infected cells. EMBO J. 39, e2020106267 (2020).

doi: 10.15252/embj.2020106267

Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917–924 (2021).

doi: 10.1038/s41591-021-01318-5

Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124 (2020).

doi: 10.1038/s41586-020-2381-y

Kim, C. et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat. Commun. 12, 288 (2021).

doi: 10.1038/s41467-020-20602-5

Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 371, 823–829 (2021).

doi: 10.1126/science.abf4830

Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).

doi: 10.1038/s41586-020-2349-y

Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014 (2020).

doi: 10.1126/science.abd0827

Jones, B. E. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci. Transl. Med. 13, eabf1906 (2021).

doi: 10.1126/scitranslmed.abf1906

Liu, L. et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584, 450–456 (2020).

doi: 10.1038/s41586-020-2571-7

Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682–687 (2020).

doi: 10.1038/s41586-020-2852-1

Haute Autorité de Santé. EVUSHELD (tixagévimab/cilgavimab) DÉCISION D’ACCÈS PRÉCOCE. https://www.has-sante.fr/jcms/p_3304034/fr/evusheld-tixagevimab/cilgavimab (2021).

Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Preprint at https://www.biorxiv.org/content/10.1101/2021.04.30.442182v5 (2022).

Simon-Loriere, E. & Schwartz, O. Towards SARS-CoV-2 serotypes? Nat. Rev. Microbiol. 20, 187–188 (2022).

doi: 10.1038/s41579-022-00708-x

Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276–280 (2021).

doi: 10.1038/s41586-021-03777-9

Pelleau, S. et al. Kinetics of the severe acute respiratory syndrome coronavirus 2 antibody response and serological estimation of time since infection. J. Infect. Dis. 224, 1489–1499 (2021).

doi: 10.1093/infdis/jiab375

Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 13, eabd2223 (2021).

doi: 10.1126/scitranslmed.abd2223

Grzelak, L. et al. Sex differences in the evolution of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2. J. Infect. Dis. 224, 983–988 (2021).

doi: 10.1093/infdis/jiab127

Hadjadj, J. et al. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2021-221508 (2022).